WO2020205544A1 - Use of ketone bodies medical imaging and diagnostics - Google Patents

Use of ketone bodies medical imaging and diagnostics Download PDF

Info

Publication number
WO2020205544A1
WO2020205544A1 PCT/US2020/025291 US2020025291W WO2020205544A1 WO 2020205544 A1 WO2020205544 A1 WO 2020205544A1 US 2020025291 W US2020025291 W US 2020025291W WO 2020205544 A1 WO2020205544 A1 WO 2020205544A1
Authority
WO
WIPO (PCT)
Prior art keywords
ketone
administration
subject
ketone body
tracer
Prior art date
Application number
PCT/US2020/025291
Other languages
French (fr)
Inventor
Douglas D. Cary
Original Assignee
Cary Douglas D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cary Douglas D filed Critical Cary Douglas D
Publication of WO2020205544A1 publication Critical patent/WO2020205544A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03Computed tomography [CT]
    • A61B6/037Emission tomography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/64Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones

Definitions

  • the present invention relates to methods for detecting and imaging molecules that are present in a non living sample or a living organism, and in particular, detecting and imaging molecules, or compositions of molecules.
  • Embodiments of the present invention employ compounds containing a ketone functional group and a radioactive or nonradioactive tracer moiety in conjunction with an imaging device such as a Positron Emission Tomography (PET) and/or a Magnetic Resonance Spectroscopic Imaging (MRS I).
  • PET Positron Emission Tomography
  • MRS I Magnetic Resonance Spectroscopic Imaging
  • Clinical imaging is well known and widely used for diagnostic and therapeutic purposes. For example, altered levels of glucose metabolism are known to be associated with the presence of various cancers, seizures, dementia and other disease states.
  • the in vivo detection and monitoring of glucose metabolism can be accomplished via the administration of a molecule with a radioactive tracer, such as fludeoxyglucose F 18 , also known as 2-deoxy-2- [ 18 F]fluorodeoxyglucose (hereinafter“F 18 DG”) to a patient and constructing a three dimensional image of the tracer concentration within the body employing a PET scanner.
  • F 18 DG 2-deoxy-2- [ 18 F]fluorodeoxyglucose
  • FDG fludeoxyglucose F 19
  • 2-deoxy-2-[ 19 F]fluorodeoxyglucose hereinafter“FDG”
  • FDG 2-deoxy-2-[ 19 F]fluorodeoxyglucose
  • the present disclosure relates to the use of ketone bodies as a tracer compound for PET and MSRI imagining.
  • the ketone bodies are modified to include a radioactive or nonradioactive tracer moiety.
  • the ketone bodies contain one or more F 18 or F 19 atoms.
  • the ketone bodies contain one or more F 18 atoms and may be administered, orally or parenterally, to a patient or subject in need of imaging using PET techniques.
  • the ketone bodies contain one or more F 19 atoms and may be administered, orally or parenterally, to a patient or subject in need of imaging using MSRI techniques.
  • the ketone bodies are labelled with an isotope of either radioactive C 14 , or nonreactive C 13 and may be administered orally or parenterally, to a patient.
  • C 14 will normally be measured by scintillation, whereas C 13 is detected by isotope mass spectrometry.
  • the terms“individual,”“subject,” or“patient” are used interchangeably. As used herein, they mean any mammal including but not limited to humans, dogs, cats, horses, cows, monkeys, rabbits, mice, and rats and guinea pigs. In some embodiments, the mammal is a human. In some embodiments, the mammal is a non-human.
  • Effective amount means the amount of a ketone body that has been modified to contain a tracer moiety and administered to a subject which will allow the medical provider or technician to obtain images of a subject’s body, body region, or body part using a specific imaging technique such as PET or MSRI.
  • the effective amount will vary depending on the tracer moiety employed in the ketone body molecule, the subject’s individual characteristics such as sex, age, weight, the desired area for imaging and the specific imaging technique.
  • administering includes any mode of administration or methods for introducing an effective amount of the ketone bodies into a subject’s body and preferably a subject’s circulatory system.
  • the methods for administering include known methods such as oral, parenteral, vaginal, rectal, ophthalmic, otic, nasal, and inhalation.
  • Parenteral methods of administration include introducing the desired amount of the ketone bodies to a subject via an injection such as subcutaneous, intramuscular, intraorbital, intracap sular, intraspinal, intrastemal or intravenous injection.
  • Parenteral administration also includes adding, mixing or diluting a composition containing the desired amount of the ketone bodies into an intravenous solution such as a Ringer’s solution or 0.9% w/v saline solution.
  • ketone bodies are provided in U.S. Patent No. 8,642,654, U.S. Patent Application Publication Nos. 2017/0196827 and 2012/0064611 and International Patent Application No. WO 2017/119986 which are incorporated herein by reference.
  • a particularly preferred ketone body is a compound of formula I:
  • the ketone body compound will be modified to incorporate a tracer moiety which may include a radioactive isotope such as C 11 , C 13 , C 14 , N 13 , O 15 , F 18 , I 124 or a combination thereof.
  • the ketone body will include a nonradioactive tracer moiety such a F 19 .
  • the ketone body will be selected form the group consisting of 3-hydroxybutyrate, acetoacetate, 3-hydroxybutyl 3-hydroxybutyrate, isomers of the forgoing and combinations thereof wherein one or more of the hydrogen atoms or hydroxyl groups is replaced with F 18 .
  • the ketone body is a compound of formula I wherein one or more of the hydrogen atoms or hydroxyl groups is replaced with F 18 .
  • the ketone body will be selected form the group consisting of 3- hydroxybutyrate, acetoacetate, 3-hydroxybutyl 3-hydroxybutyrate, isomers of the forgoing and combinations thereof wherein one or more of the hydrogen atoms or hydroxyl groups is replaced with F 19 .
  • the ketone body is a compound of formula I wherein one or more of the hydrogen atoms or hydroxyl groups is replaced with F 19 .
  • the ketone body will be selected form the group consisting of 3-hydroxybutyrate, acetoacetate, 3-hydroxybutyl 3-hydroxybutyrate, isomers of the forgoing and combinations thereof wherein one or more of the carbon atoms are replaced with C 13 or C 14 .
  • the ketone body with a tracer moiety may be prepared by any method known in the art. For example methods for preparing the ketone body of formula I are provided in U.S. Patent Application Publication No. 2012/0064611. Once the compound of formula I is prepared, one of the hydroxyl groups may be protected with a protecting group such as an acetyl protecting group and the other hydroxyl group may be replaced with a triflate.
  • a protecting group such as an acetyl protecting group
  • the hydroxyl protected, triflate derivative of the compound of formula I is then reacted an F 18 source such as [(crypt- 222)K] + 18 F so the F 18 anion replaces the triflate moiety and the cryptand and hydroxyl protecting group are removed to produce the F 18 ketone body of a compound of formula I that may be used in the methods of the present invention.
  • F 18 source such as [(crypt- 222)K] + 18 F
  • F 18 anion replaces the triflate moiety and the cryptand and hydroxyl protecting group are removed to produce the F 18 ketone body of a compound of formula I that may be used in the methods of the present invention.
  • a skilled artisan would also know how to incorporate one or more F 19 atoms into a ketone body, including a compound of formula I using the methods described herein for producing F 18 ketone bodies.
  • the ketone bodies with the tracer moiety may be administered to a subject either orally or parenterally.
  • the oral administration may comprise the step of orally administering to a subject a solid or liquid composition comprising an effective amount of the ketone body with the tracer moiety and at least one pharmaceutically acceptable excipient such as a carrier, diluent, binder, glidant, solubilizing agent, wetting agent, emulsifier, preservative, lubricant, flavoring agent, pH adjusting agent, or combinations thereof.
  • parenteral administration may involve the step of parenterally administering, preferably intravenously, a composition comprising an effective amount of the ketone body with the tracer moiety and at least one pharmaceutically acceptable excipient such as a carrier, diluent, buffer, solubilizing agent, wetting agent, emulsifier, preservative, tonicity agent (osmolality agent), pH adjusting agent, or combinations thereof.
  • a pharmaceutically acceptable excipient such as a carrier, diluent, buffer, solubilizing agent, wetting agent, emulsifier, preservative, tonicity agent (osmolality agent), pH adjusting agent, or combinations thereof.
  • the parenteral compositions comprise: (i) an effective amount of the ketone body with the tracer moiety; (ii) a liquid carrier such as water, glycerin, polyethylene glycol or combinations thereof; and (iii) optionally one or more pharmaceutical excipients selected from the group consisting of a buffer, a solubilizing agent, a wetting agent, an emulsifier, a preservative, a tonicity agent (osmolality agent), a pH adjusting agent, or combinations thereof.
  • the parenteral composition may also comprise an effective amount of the ketone body dispersed or dissolved in a conventional intravenous fluid such as 0.9% w/v saline or Ringer’s solution.
  • the oral compositions comprise: (i) an effective amount of the ketone body with the tracer moiety; (ii) a solid or liquid carrier and (iii) optionally one or more pharmaceutical excipients selected from the group consisting of a buffer, a solubilizing agent, a wetting agent, an emulsifier, a preservative, a tonicity agent (osmolality agent), a pH adjusting agent, a thickening or viscosity enhancing agent or combinations thereof. If the oral composition is a liquid composition, it may be a solution, suspension or emulsion.
  • liquid carriers examples include but are not limited to water and polyols such as, glycerin, polyethylene glycol or combinations thereof. If the oral composition is a solid composition, it may be a tablet, capsule, powder, pellets or granules.
  • solid carries examples include celluloses such as powdered cellulose, microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, and methylcellulose, croscarmellose sodium, crospovidone, starch, pergelatinized starch, sodium starch glycolate, calcium carbonate, calcium phosphate, calcium sulfate, kaolin, and combinations thereof.
  • the solid oral compositions may further optionally, comprise a binder, diluent, lubricant or combination thereof.
  • the solid oral compositions should dissolve or disintegrate within 60 minutes or less, preferably 45 minutes or less and more preferably within 30 minutes of less when tested with an appropriate United States Pharmacopeia dissolution or disintegration testing apparatus.
  • compositions comprising the effective amount of the ketone bodies with a tracer moiety be free of any sugar such as glucose, sucrose, lactose, etc. which would interfere with the absorption and/or action of the ketone body at the desired location such as a tumor.
  • the effective amount of the ketone body with an F 18 tracer moiety that may be administered either orally or parenterally, preferably intravenously should range from an amount about 150 to about 600 MBq of F 18 , preferably about 200 to about 500 MBq of F 18 and more preferably about 250 to about 450 MBq of F 18 . If the ketone bodies with an F 18 tracer moiety is employed in the methods of the present disclosure, the administration should occur when the subject is in a fasted stated.
  • the subject should have refrained from eating or drinking anything except water or black coffee for at least 4-12 hours prior to administration of the ketone body and preferably at least 4-6 hours prior to admiration of the ketone body. It is also desirable that subject’s blood glucose level be less than 160 mg/dL, preferably less than 150 mg/dL and most preferably less than 140 mg/dL at the time of administration of the ketone body.
  • the imaging using a device such as a PET scanner should begin within 20-120 minutes after administration, preferably, within 30-90 minutes after administration and most preferably within 30 to 60 minutes after administration.
  • about 250 to about 450 MBq of one or more ketone bodies with an F 18 tracer moiety are administered to human subjects in a fasted stated and after about 30 to 90 minutes of administration the subject receives a PET or PET/CT scan and the resulting images may be used to:
  • the effective amount of the ketone body with an F 19 tracer moiety should range from an amount about 100 mg to about 2,500 mg, preferably about 250 mg to about 2,000 mg and most preferably about 500 mg to about 1,500 mg. If the administration is oral the total dose of the ketone body with an F 19 tracer moiety may be administered in a single or divided doses. For example a total of 2,000 mg may be orally administered by having the patient swallow four (4) tablets containing 500 mg of the ketone body with an F 19 tracer moiety.
  • the administration should occur when the subject is in a fasted stated. More specifically, the subject should have refrained from eating or drinking anything except water or black coffee for at least 4- 12 hours prior to administration of the ketone body and preferably at least 4-6 hours prior to admiration of the ketone body. It is also desirable that subject’s blood glucose level be less than 160 mg/dL, preferably less than 150 mg/dL and most preferably less than 140 mg/dL at the time of administration of the ketone body.
  • the imaging using a device such as an MSRI scanner should begin within 20-120 minutes after administration, preferably, within 30-90 minutes after administration and most preferably within 30 to 60 minutes after administration.
  • the ketone body with an F 19 tracer moiety may be used to generate images to:
  • An F 18 ketone body may be prepared by the general reaction scheme shown below:
  • An F 18 ketone body may be prepared by the general reaction scheme shown below:
  • An F 18 ketone body may be prepared by the general reaction scheme shown below:
  • the ketone bodies with F 18 tracer moieties prepared in Examples 1, 2 or 3 may be mixed with 0.25 to 1 ml of USP water for injection and about 300 to 400 MBq of the F 18 ketone bodies are intravenously administered to an adult male or female subject that fasted for 4-6 hours prior to administration. After 30 to 60 minutes the subject may receive a full body PET scan.
  • Tablets containing the ketone bodies with F 19 tracer moieties prepared in Example 4 can be prepared using conventional tableting techniques such as wet and dry granulation and/or slugging and compressing the results granules or powders into tablets using a conventional tablet press.
  • the tablets may have the following compositions:
  • the ketone bodies with F 19 tracer moieties prepared in Example 5 may be mixed with conventional excipients as previously described to prepare capsules, powders, solutions, suspensions or tablets as described in Example 6 orally administered in an amount of about 1,000- 1,500 mg to an adult male or female subject that fasted for 4-6 hours prior to administration. After 30 to 60 minutes the subject may receive an MSRI scan.
  • any of the terms“comprising,”“consisting essentially of’ and“consisting of’ may be replaced with either of the other two terms.
  • the terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The disclosure relates to the use of ketone containing compounds that have been modified with a radioactive or nonradioactive tracer moiety to medical imaging and diagnostics.

Description

USE OF KETONE BODIES FOR MEDICAL IMAGING AND DIAGNOSTICS
This application claims the benefits of U.S. Provisional Patent Application No.
62/825,963 filed on March 29, 2019 which is incorporated herein by reference.
FIELD OF THE INVENTION
The present invention relates to methods for detecting and imaging molecules that are present in a non living sample or a living organism, and in particular, detecting and imaging molecules, or compositions of molecules. Embodiments of the present invention employ compounds containing a ketone functional group and a radioactive or nonradioactive tracer moiety in conjunction with an imaging device such as a Positron Emission Tomography (PET) and/or a Magnetic Resonance Spectroscopic Imaging (MRS I).
BACKGROUND OF THE INVENTION
Clinical imaging is well known and widely used for diagnostic and therapeutic purposes. For example, altered levels of glucose metabolism are known to be associated with the presence of various cancers, seizures, dementia and other disease states. The in vivo detection and monitoring of glucose metabolism can be accomplished via the administration of a molecule with a radioactive tracer, such as fludeoxyglucose F18, also known as 2-deoxy-2- [18F]fluorodeoxyglucose (hereinafter“F18DG”) to a patient and constructing a three dimensional image of the tracer concentration within the body employing a PET scanner. The image generated by the F18DG concentration allows the medical professional to determine the location of a cancerous tumor and the extent of metastasis. The use of nonradioactive tracer compounds such as fludeoxyglucose F19, also known as 2-deoxy-2-[19F]fluorodeoxyglucose (hereinafter“FDG”) has also been reported in the literature. For example, U.S. Patent Nos. 9,207,298 and 9,014,785, which are incorporated herein by reference, describe the use of FDG as a tracer for use in MRSI imaging techniques.
U.S. Patent No. 8,642,654, which is incorporated herein by reference, describes ketone bodies that may be used as a source of energy in most tissues of the body and suggests that the administration of pharmaceutically and physiologically safe ketone bodies can lead to various clinical benefits, including an enhancement of physical and cognitive performance and the treatment of cardiovascular conditions, diabetes, neurodegenerative diseases and epilepsy.
SUMMARY OF THE INVENTION
The present disclosure relates to the use of ketone bodies as a tracer compound for PET and MSRI imagining. The ketone bodies are modified to include a radioactive or nonradioactive tracer moiety.
In certain embodiments, the ketone bodies contain one or more F18 or F19 atoms.
In certain embodiments, the ketone bodies contain one or more F18 atoms and may be administered, orally or parenterally, to a patient or subject in need of imaging using PET techniques.
In certain embodiments, the ketone bodies contain one or more F19 atoms and may be administered, orally or parenterally, to a patient or subject in need of imaging using MSRI techniques.
In certain embodiments, the ketone bodies are labelled with an isotope of either radioactive C14, or nonreactive C13 and may be administered orally or parenterally, to a patient. C14 will normally be measured by scintillation, whereas C13 is detected by isotope mass spectrometry.
DETAILED DESCRIPTION OF THE INVENTION
Except where noted, all terms are intended to have their normal meaning in the art, and are used as they would have been used by a person of ordinary skill at the time of the disclosure. It should be understood that throughout this application the singular forms, such as“a,”“an,” and “the,” are often used for convenience, however, these singular forms are intended to encompass the plural unless otherwise specified, or unless the context clearly calls for the singular alone. It should also be understood that all publication, patents, books, journal articles, and the like, which are referred to in this application, are incorporated by reference in their entirety and for all purposes to the extent not inconsistent with the present disclosure.
Concentration, weight percent and other numerical data may be presented herein in a range format. It is to be understood that such range format is used merely for convenience and brevity and should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. For example, a percent range of 1% to 20% should be interpreted to include not only the explicitly recited percent limits of 1% and 20% but also to include individual percentages such as 1.25%, 2.49%, 3%, 4.75%, 8.34% and sub-ranges such as 1% to 5%, 10% to 15%, 4.7% to 11.9% etc.
The terms“individual,”“subject,” or“patient” are used interchangeably. As used herein, they mean any mammal including but not limited to humans, dogs, cats, horses, cows, monkeys, rabbits, mice, and rats and guinea pigs. In some embodiments, the mammal is a human. In some embodiments, the mammal is a non-human.
“Effective amount” means the amount of a ketone body that has been modified to contain a tracer moiety and administered to a subject which will allow the medical provider or technician to obtain images of a subject’s body, body region, or body part using a specific imaging technique such as PET or MSRI. The effective amount will vary depending on the tracer moiety employed in the ketone body molecule, the subject’s individual characteristics such as sex, age, weight, the desired area for imaging and the specific imaging technique.
“Administering” and related terms such as “administration,” “administer” and “administered” includes any mode of administration or methods for introducing an effective amount of the ketone bodies into a subject’s body and preferably a subject’s circulatory system. The methods for administering include known methods such as oral, parenteral, vaginal, rectal, ophthalmic, otic, nasal, and inhalation. Parenteral methods of administration include introducing the desired amount of the ketone bodies to a subject via an injection such as subcutaneous, intramuscular, intraorbital, intracap sular, intraspinal, intrastemal or intravenous injection. Parenteral administration also includes adding, mixing or diluting a composition containing the desired amount of the ketone bodies into an intravenous solution such as a Ringer’s solution or 0.9% w/v saline solution.
As used herein the term“ketone body” or“ketone bodies” refers to any molecule that contains a ketone moiety, i.e., a carbonyl group bonded to two carbon atoms (R2-C=0 wherein R is not H) and that may be used as a source of energy in most animal tissues. Examples of ketone bodies are provided in U.S. Patent No. 8,642,654, U.S. Patent Application Publication Nos. 2017/0196827 and 2012/0064611 and International Patent Application No. WO 2017/119986 which are incorporated herein by reference. Specific examples of ketone bodies that may be used in the present invention include but are not limited to (R)-3-hydroxybutyrate, acetoacetate, 3- hydroxybutyl 3-hydroxybutyrate and the isomers thereof including (3R)-hydroxybutyl(3R)- hydroxybutyrate. A particularly preferred ketone body is a compound of formula I:
Figure imgf000006_0001
In accordance with the present invention, the ketone body compound will be modified to incorporate a tracer moiety which may include a radioactive isotope such as C11, C13, C14, N13, O15, F18, I124 or a combination thereof. Alternatively, the ketone body will include a nonradioactive tracer moiety such a F19.
In a preferred embodiment, the ketone body will be selected form the group consisting of 3-hydroxybutyrate, acetoacetate, 3-hydroxybutyl 3-hydroxybutyrate, isomers of the forgoing and combinations thereof wherein one or more of the hydrogen atoms or hydroxyl groups is replaced with F18. In a particularly preferred embodiment, the ketone body is a compound of formula I wherein one or more of the hydrogen atoms or hydroxyl groups is replaced with F18.
In another embodiment, the ketone body will be selected form the group consisting of 3- hydroxybutyrate, acetoacetate, 3-hydroxybutyl 3-hydroxybutyrate, isomers of the forgoing and combinations thereof wherein one or more of the hydrogen atoms or hydroxyl groups is replaced with F19. In a particularly preferred embodiment, the ketone body is a compound of formula I wherein one or more of the hydrogen atoms or hydroxyl groups is replaced with F19. In yet another embodiment, the ketone body will be selected form the group consisting of 3-hydroxybutyrate, acetoacetate, 3-hydroxybutyl 3-hydroxybutyrate, isomers of the forgoing and combinations thereof wherein one or more of the carbon atoms are replaced with C13 or C14.
The ketone body with a tracer moiety may be prepared by any method known in the art. For example methods for preparing the ketone body of formula I are provided in U.S. Patent Application Publication No. 2012/0064611. Once the compound of formula I is prepared, one of the hydroxyl groups may be protected with a protecting group such as an acetyl protecting group and the other hydroxyl group may be replaced with a triflate. The hydroxyl protected, triflate derivative of the compound of formula I is then reacted an F18 source such as [(crypt- 222)K]+ 18F so the F18 anion replaces the triflate moiety and the cryptand and hydroxyl protecting group are removed to produce the F18 ketone body of a compound of formula I that may be used in the methods of the present invention. A skilled artisan would also know how to incorporate one or more F19 atoms into a ketone body, including a compound of formula I using the methods described herein for producing F18 ketone bodies.
The ketone bodies with the tracer moiety, preferably an F18 or F19 tracer moiety, may be administered to a subject either orally or parenterally. The oral administration may comprise the step of orally administering to a subject a solid or liquid composition comprising an effective amount of the ketone body with the tracer moiety and at least one pharmaceutically acceptable excipient such as a carrier, diluent, binder, glidant, solubilizing agent, wetting agent, emulsifier, preservative, lubricant, flavoring agent, pH adjusting agent, or combinations thereof. Similarly the parenteral administration may involve the step of parenterally administering, preferably intravenously, a composition comprising an effective amount of the ketone body with the tracer moiety and at least one pharmaceutically acceptable excipient such as a carrier, diluent, buffer, solubilizing agent, wetting agent, emulsifier, preservative, tonicity agent (osmolality agent), pH adjusting agent, or combinations thereof. Examples of the various excipients that may be employed in the compositions described herein can be found various reference materials such as the United States Pharmacopeia (“USP”) 29 (2006) pp. 3256-3261 and Rowe et ah, eds., Handbook of Pharmaceutical Excipients, 6th ed. 2009.
In certain embodiments, the parenteral compositions comprise: (i) an effective amount of the ketone body with the tracer moiety; (ii) a liquid carrier such as water, glycerin, polyethylene glycol or combinations thereof; and (iii) optionally one or more pharmaceutical excipients selected from the group consisting of a buffer, a solubilizing agent, a wetting agent, an emulsifier, a preservative, a tonicity agent (osmolality agent), a pH adjusting agent, or combinations thereof. As indicated above the parenteral composition may also comprise an effective amount of the ketone body dispersed or dissolved in a conventional intravenous fluid such as 0.9% w/v saline or Ringer’s solution.
In certain embodiments, the oral compositions comprise: (i) an effective amount of the ketone body with the tracer moiety; (ii) a solid or liquid carrier and (iii) optionally one or more pharmaceutical excipients selected from the group consisting of a buffer, a solubilizing agent, a wetting agent, an emulsifier, a preservative, a tonicity agent (osmolality agent), a pH adjusting agent, a thickening or viscosity enhancing agent or combinations thereof. If the oral composition is a liquid composition, it may be a solution, suspension or emulsion. Examples of liquid carriers that may be used in the liquid oral formulations, include but are not limited to water and polyols such as, glycerin, polyethylene glycol or combinations thereof. If the oral composition is a solid composition, it may be a tablet, capsule, powder, pellets or granules. Examples of solid carries that may be used in the solid oral formulations include celluloses such as powdered cellulose, microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, and methylcellulose, croscarmellose sodium, crospovidone, starch, pergelatinized starch, sodium starch glycolate, calcium carbonate, calcium phosphate, calcium sulfate, kaolin, and combinations thereof. The solid oral compositions may further optionally, comprise a binder, diluent, lubricant or combination thereof. The solid oral compositions should dissolve or disintegrate within 60 minutes or less, preferably 45 minutes or less and more preferably within 30 minutes of less when tested with an appropriate United States Pharmacopeia dissolution or disintegration testing apparatus.
In certain embodiments, it is desired that the compositions comprising the effective amount of the ketone bodies with a tracer moiety be free of any sugar such as glucose, sucrose, lactose, etc. which would interfere with the absorption and/or action of the ketone body at the desired location such as a tumor.
In the case of ketone bodies with a radioactive tracer moiety such as F18, the effective amount of the ketone body with an F18 tracer moiety that may be administered either orally or parenterally, preferably intravenously, should range from an amount about 150 to about 600 MBq of F18, preferably about 200 to about 500 MBq of F18 and more preferably about 250 to about 450 MBq of F18. If the ketone bodies with an F18 tracer moiety is employed in the methods of the present disclosure, the administration should occur when the subject is in a fasted stated. More specifically, the subject should have refrained from eating or drinking anything except water or black coffee for at least 4-12 hours prior to administration of the ketone body and preferably at least 4-6 hours prior to admiration of the ketone body. It is also desirable that subject’s blood glucose level be less than 160 mg/dL, preferably less than 150 mg/dL and most preferably less than 140 mg/dL at the time of administration of the ketone body. After the effective amount of the ketone body with the tracer moiety is administered, the imaging using a device such as a PET scanner should begin within 20-120 minutes after administration, preferably, within 30-90 minutes after administration and most preferably within 30 to 60 minutes after administration.
In certain embodiments, about 250 to about 450 MBq of one or more ketone bodies with an F18 tracer moiety are administered to human subjects in a fasted stated and after about 30 to 90 minutes of administration the subject receives a PET or PET/CT scan and the resulting images may be used to:
i. Differentiate or diagnosis benign from malignant lesions or tumors;
ii. Locate an unknown primary tumor when metastatic disease is discovered as the first manifestation of cancer or when the subject presents with a paraneoplastic syndrome;
iii. Monitor or measure the effect of therapies on known malignancies;
iv. Determine optimal sites for a biopsy;
v. Guide radiation therapy;
vi. Evaluate or diagnosis infections
vii. Evaluate or diagnosis cardiovascular conditions such as atherosclerosis;
viii. Evaluate or diagnosis neurodegenerative conditions; and
ix. Evaluate or diagnosis seizures and epilepsy.
In the case of ketone bodies with a radioactive tracer moiety such as F19, the effective amount of the ketone body with an F19 tracer moiety that may be administered either orally or parenterally, should range from an amount about 100 mg to about 2,500 mg, preferably about 250 mg to about 2,000 mg and most preferably about 500 mg to about 1,500 mg. If the administration is oral the total dose of the ketone body with an F19 tracer moiety may be administered in a single or divided doses. For example a total of 2,000 mg may be orally administered by having the patient swallow four (4) tablets containing 500 mg of the ketone body with an F19 tracer moiety. If the ketone bodies with an F19 tracer moiety is employed in the methods of the present disclosure, the administration should occur when the subject is in a fasted stated. More specifically, the subject should have refrained from eating or drinking anything except water or black coffee for at least 4- 12 hours prior to administration of the ketone body and preferably at least 4-6 hours prior to admiration of the ketone body. It is also desirable that subject’s blood glucose level be less than 160 mg/dL, preferably less than 150 mg/dL and most preferably less than 140 mg/dL at the time of administration of the ketone body. After the effective amount of the ketone body with the tracer moiety is administered, the imaging using a device such as an MSRI scanner should begin within 20-120 minutes after administration, preferably, within 30-90 minutes after administration and most preferably within 30 to 60 minutes after administration. The ketone body with an F19 tracer moiety may be used to generate images to:
i. Differentiate or diagnosis benign from malignant lesions or tumors;
ii. Classify solid tumors as either glucose positive or ketone positive;
iii. Locate an unknown primary tumor when metastatic disease is discovered as the first manifestation of cancer or when the subject presents with a paraneoplastic syndrome;
iv. Monitor or measure the effect of therapies on known malignancies;
v. Determine optimal sites for a biopsy;
vi. Guide radiation therapy;
vii. Evaluate or diagnosis infections
viii. Evaluate or diagnosis cardiovascular conditions such as atherosclerosis; ix. Evaluate or diagnosis neurodegenerative conditions; and
x. Evaluate or diagnosis seizures and epilepsy.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following are provided by way of example only and are by no means intended to be limiting.
Example 1
An F18 ketone body may be prepared by the general reaction scheme shown below:
Figure imgf000012_0001
Figure imgf000013_0001
wherein Ac is CH3CO and Tf is CF3SO2.
Example 2
An F18 ketone body may be prepared by the general reaction scheme shown below:
Figure imgf000013_0002
Figure imgf000014_0002
wherein Ac is CH3CO and Tf is CF3SO2.
Example 3
An F18 ketone body may be prepared by the general reaction scheme shown below:
Figure imgf000014_0001
wherein Ac is CH3CO and Tf is CF3SO2. Example 4
The ketone bodies with F18 tracer moieties prepared in Examples 1, 2 or 3 may be mixed with 0.25 to 1 ml of USP water for injection and about 300 to 400 MBq of the F18 ketone bodies are intravenously administered to an adult male or female subject that fasted for 4-6 hours prior to administration. After 30 to 60 minutes the subject may receive a full body PET scan.
Example 5
The ketone bodies with F19 tracer moieties prepared according to the above procedures of Examples 1, 2 or 3 wherein the F18 is replaced with F19.
Example 6
Tablets containing the ketone bodies with F19 tracer moieties prepared in Example 4 can be prepared using conventional tableting techniques such as wet and dry granulation and/or slugging and compressing the results granules or powders into tablets using a conventional tablet press. The tablets may have the following compositions:
Figure imgf000016_0001
Example 7
The ketone bodies with F19 tracer moieties prepared in Example 5 may be mixed with conventional excipients as previously described to prepare capsules, powders, solutions, suspensions or tablets as described in Example 6 orally administered in an amount of about 1,000- 1,500 mg to an adult male or female subject that fasted for 4-6 hours prior to administration. After 30 to 60 minutes the subject may receive an MSRI scan.
The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein, any of the terms“comprising,”“consisting essentially of’ and“consisting of’ may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

Claims

1. A method for detecting and imaging molecules that are present in a subject comprising the steps of: (i) administering an effective amount of a ketone body that has be modified to include a radioactive or nonradioactive tracer moiety and (ii) obtaining images of the subject using a Positron Emission Tomography (PET) and/or a Magnetic Resonance Spectroscopic Imaging (MRSI).
2. The method of claim 1 wherein the radioactive tracer moiety is F18.
3. The method of claim 1 wherein the nonradioactive tracer moiety is F19.
4. The method of claim 1 wherein the ketone body is selected form the group consisting of
3-hydroxybutyrate, acetoacetate, 3-hydroxybutyl 3-hydroxybutyrate, isomers of the forgoing and combinations thereof.
5. The method of claim 1 wherein the administration is oral.
6. The method of claim 1 wherein the administration is parenteral.
7. The method of claim 1 wherein the administration is under fasting conditions.
8. The method of claim 1 wherein the radioactive tracer moiety is C14.
9. The method of claim 1 wherein the nonradioactive tracer moiety is C13.
PCT/US2020/025291 2019-03-29 2020-03-27 Use of ketone bodies medical imaging and diagnostics WO2020205544A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825963P 2019-03-29 2019-03-29
US62/825,963 2019-03-29

Publications (1)

Publication Number Publication Date
WO2020205544A1 true WO2020205544A1 (en) 2020-10-08

Family

ID=72667534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/025291 WO2020205544A1 (en) 2019-03-29 2020-03-27 Use of ketone bodies medical imaging and diagnostics

Country Status (1)

Country Link
WO (1) WO2020205544A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2518889A1 (en) * 2003-03-13 2004-09-23 Amersham Health As Methods of radiofluorination of biologically active vectors
WO2018080394A1 (en) * 2016-10-28 2018-05-03 Agency For Science, Technology And Research Hyperpolarized [3- 13c]acetoacetate and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2518889A1 (en) * 2003-03-13 2004-09-23 Amersham Health As Methods of radiofluorination of biologically active vectors
WO2018080394A1 (en) * 2016-10-28 2018-05-03 Agency For Science, Technology And Research Hyperpolarized [3- 13c]acetoacetate and methods of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOUTELDJA N. ET AL.: "Using positron emission tomography to study human ketone body metabolism: a review", METABOLISM, vol. 63, no. 11, 2014, pages 1375 - 1384, XP029075186, DOI: 10.1016/j.metabol.2014.08.001 *

Similar Documents

Publication Publication Date Title
De Jong et al. Visualisation of bladder cancer using 11 C-choline PET: first clinical experience
Yao et al. Infection imaging with 18F-FDS and first-in-human evaluation
US20220387635A1 (en) Pet imaging of cancerous cells using 18f-fluoroacetate
JP2019527225A5 (en)
Ell et al. Functional imaging of the brain
DK2572735T3 (en) Diagnostic imaging by combining contrast agents
Alameen et al. Radiobiological risks in terms of effective dose and organ dose from 18F-FDG whole-body PET/CT procedures
Yu et al. Assessment of 18 F-labeled mitochondrial complex I inhibitors as PET myocardial perfusion imaging agents in rats, rabbits, and primates
JP2005226021A (en) Compound having affinity to mannose receptor
Kung et al. Prevalence of detecting unknown cerebral metastases in fluorodeoxyglucose positron emission tomography/computed tomography and its potential clinical impact
WO2020205544A1 (en) Use of ketone bodies medical imaging and diagnostics
JP5213702B2 (en) Dyspepsia diagnostic test
US11504439B2 (en) Radioactive compound for diagnosis of malignant melanoma and use thereof
CN111655298B (en) Diagnostic formulation for magnetic resonance of neoplastic diseases comprising deuterated 3-O-methylglucose and diagnostic method using said formulation
KR102369838B1 (en) A Contrast Agent Composition for Detecting Lesional Margin of Astrocytosis-Related Disease Comprising Quinoline Derivatives as Active Ingredients
WO2017051519A1 (en) In vivo imaging agent
JP6329302B2 (en) Novel polysaccharide metal complex compound recognizing macrophage mannose receptor and pharmaceutical composition thereof
US20230284994A1 (en) Pet-ct imaging methods, contrast agents and pharmaceutical compositions for use in said imaging methods
WO2010013139A2 (en) Radionuclide-labeled erlotinib
KR102369854B1 (en) A Contrast Agent Composition for Detecting Lesional Margin of Astrocytosis-Related Disease Comprising C11-Acetate as an Active Ingredient
US12082918B2 (en) Preparation for magnetic resonance diagnostics for oncological diseases, comprising deuterated 2-amino-2-methylpropionic acid and/or 2-(N-methylamino)-2-methylpropionic acid, and diagnostic method using said preparation
KR20240054325A (en) Compounds useful for PET-imaging of Bruton's tyrosine kinase
Thapa et al. Imaging b-Cell Function Using a Zinc-Responsive MRI Contrast Agent May Identify First Responder Islets
JP2014181309A (en) Novel polysaccharide metal complex compound recognizing macrophage mannose receptor and pharmaceutical composition thereof
KR20210128125A (en) A Contrast Agent Composition for Detecting Lesional Margin of Dementia Caused by Degenerative Brain Disease Comprising Quinoline Derivatives as Active Ingredients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20785244

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20785244

Country of ref document: EP

Kind code of ref document: A1